Inês Martins holds a BSc in Cell and Molecular Biology from Universidade Nova de Lisboa and is currently finishing her PhD in Biomedical Sciences at Universidade de Lisboa. Her work has been focused on blood vessels and their role in both hematopoiesis and cancer development.
Rubraca (rucaparib), Clovis Oncology‘s PARP inhibitor, shrank tumors in 44% of metastatic castration-resistant prostate cancer (mCRPC) patients with BRCA mutations included in a Phase 2 clinical trial, the company ... Read more
A combination of surgery and radiation therapy is better at extending the survival of men with locally advanced prostate cancer than radiation therapy plus hormone therapy, but is associated ... Read more
Patients with castration-resistant prostate cancer (CRPC) who are at high risk for developing metastasis may safely add Erleada (apalutamide) to androgen deprivation therapy without worrying about their quality of life, ... Read more
Patients with metastatic castration-resistant prostate cancer do not benefit from the addition of Reolysin (pelareorep) to Taxotere (docetaxel), according to recent data from a Phase 2 trial. The trial (NCT01619813) failed to ... Read more
Combining BioXcel‘s BXCL701 with immune checkpoint inhibitors may potentially help treat men with castration-resistant prostate cancer (CRPC), says the Branford, Conn., pharma company. Dr. Luca Rastelli, BioXCel’s vice-president for oncology ... Read more